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Background: Prevalence of cytomegalovirus (CMV) infection is 90–100% in developing countries; however, the
kinetics of anti-CMV IgG in infants remains elusive.
Methods: Sera from 112 mother-newborn pairs and longitudinal samples from 41 infants up to 2-year old were
tested for anti-CMV IgG and IgM. Additionally, samples from 837 healthy children were included.
Results: Of 112 mothers, 108 (96.4%) were anti-CMV IgG positive; their 108 newborns were also seropositive. In a
2-year follow-up among 40 infants of positive mothers, anti-CMV IgG level in 8 individuals decreased with time and
became undetectable by age of 3.5–8 months, and that in 32 others decreased at 1- and 3.5-month old, and then
increased. Based on the positive IgM, rising IgG levels, and low anti-CMV IgG avidity index, 76.7% of the primary
infections were demonstrated to occur during 1–3.5 months of age. The overall seroprevalence of anti-CMV in 837
children was 82.4%, which was generally constant from 2 to 8 years old (χ2 = 3.150, p = 0.790).
Conclusions: The maternally acquired anti-CMV IgG in infants disappears before 8-month old. Primary CMV
infection in Chinese children mostly occurs during 1–3.5 months of age. Whether the relatively lower
seroprevalence of anti-CMV in Chinese children found in this survey may reflect the positive rate in child-bearing
age women in the future remains to be further studied.
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Human cytomegalovirus (CMV) infection is ubiquitous
throughout the world. It is well documented that the
seroprevalence of CMV in young women of childbearing
age is 40–80% and 90–100% in developed and developing
countries respectively [1]. CMV is the most common
cause of viral intrauterine infection, with an incidence of
0.03–2.0% in all live births [1,2]. Congenital CMV infec-
tion can cause birth defects such as mental retardation,
and increase the risk of morbidity and mortality in new-
borns [3-5]. Studies demonstrated that preconception* Correspondence: yzh20061111@yahoo.com; dtylhu@126.com
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reproduction in any medium, provided the ormaternal immunity to CMV provides substantial protec-
tion against vertical transmission and decrease the inci-
dence of diseases and permanent physical sequelae in
infants [6,7]. Although various mechanisms may account
for these findings, an important explanation is the trans-
placental immunity mediated by maternal IgG antibodies
in the fetus [8]. To date, the immunologic events after
transplacental transfer of maternal anti-CMV IgG in
infants are poorly characterized. In addition, although as
high as 90–100% women in developing countries are anti-
CMV IgG positive, the age of primary CMV infection in
general population remains elusive.
In the present study, we compared the anti-CMV IgG
concentrations between maternal and cord sera to
characterize transplacental transfer of maternal anti-
CMV IgG. Furthermore, we studied the evolution of
anti-CMV IgG in the longitudinal serum samples withintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Correlation of transplacentally transferred anti-CMV
IgG in infants with the maternal antibody. Anti-CMV IgG level in
the cord blood was correlated with that in mothers (linear
regression analysis, y = 1.04x + 105.09, r = 0.87, p < 0.001, n = 108).
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anti-CMV IgG among children by different ages.
Results
Transplacental transfer of maternal anti-CMV IgG
Of the 112 mothers, 108 (96.4%) were anti-CMV IgG
positive. To investigate transplacental transfer of maternal
anti-CMV IgG, we quantified the IgG in 108 mother-
newborn pairs. Each mother transferred anti-CMV IgG to
her newborn, because the IgG was positive in each cord
serum. The geometric mean concentration (GMC) of
anti-CMV IgG in the cord blood (770.3 IU/ml, range
106.1–2407.3) was higher than that in the mother
(654.2 IU/ml, 96.1–2351.7). In details, 75% of the cord
sera had higher concentrations than the corresponding
maternal sera (Table 1). Anti-CMV IgG level in the cord
blood was correlated with that in mothers (Figure 1). The
pregnant woman’s age, child’s age, and body weight were
not correlated with the transplacental transfer efficiency
(data not shown).
Dynamic changes of anti-CMV IgG and IgM after birth
Forty-one children with longitudinal serum specimens were
retrospectively measured for anti-CMV IgG and IgM. In
one child of a mother with negative anti-CMV IgG, anti-
CMV IgG and IgM were persistently negative in the cord
blood and during the 24-month follow-up; we excluded this
child in the further analysis. Thus, 40 mother-child pairs
were included in the analysis of the dynamic changes of
maternal anti-CMV IgG. The GMC of anti-CMV IgG in
the mothers and newborns was 759.8 IU/ml (232.1–2351.7)
and 976.5 IU/ml (227.3–1935.0), respectively.
Of these children, the IgG concentration in 8 indivi-
duals decreased with time and became undetectable as
early as 3.5–8 months after birth (Table 2), demonstrat-
ing that the maternally acquired anti-CMV IgG in
infants disappears before 8-month old. In 32 others, the
IgG levels decreased before 3.5-month old, but signifi-
cantly increased at 8-month old, and slightly decreased
at 2 years of age (Table 2). The GMC of anti-CMV IgG
in the 8 and 32 corresponding mothers was 672.4 IU/mlTable 1 Comparison of anti-CMV IgG between newborns and
Ratio of cord/maternal anti-CMV No. (%)
M
GMCa
≥1.5 15 (13.9) 349.1
1.01–1.49 66 (61.1) 686.0
1 2 (1.9) 744.0
0.30–0.99 25 (23.1) 832.7
Total 108 (100) 654.2
aGMC is the abbreviation of geometric mean concentration.(264.2–1753.6) and 791.4 IU/ml (232.1–2351.7), respect-
ively (t = 0.354, p = 0.726). The profile of the IgG level
after birth was further analyzed between the two groups
(Table 2). At both 0- and 1-month-old, the IgG levels in
two groups were not statistically different and decreased
in a similar extent. However, at 3.5-month-old, the re-
duction of the IgG levels was less obvious in the 32 chil-
dren. Thereafter, the IgG levels increased significantly in
the 32 children, but became persistently negative in the
8 children.
None of the 112 cord blood showed positive for anti-
CMV IgM. Anti-CMV IgM was also tested in 30 infected
individuals with sufficient samples (Table 3). The IgM
was positive in 27 children and was persistently negative
in longitudinal sera of 3 other individuals. Together with
the anti-CMV IgG kinetics (Table 2), the results strongly
suggested that CMV infection was not congenitally, but
postnatally, acquired.mothers
Anti-CMV IgG (IU/ml) p
others Newborns
Range GMC Range
113.2–855.8 683.2 230.4–1728.9 <0.001
96.1–2219.6 826.8 106.1–2407.3 <0.001
650.1–851.3 744.0 650.1–851.3 -
252.5–2351.7 688.9 240.3–1796.2 0.001
96.1–2351.7 770.3 106.1–2407.3 <0.001
Table 2 Kinetics of anti-CMV IgG level in infected and uninfected children after birth
Age (month) Anti-CMV IgG (IU/ml) Statistics
Infected children (n = 32) Uninfected children (n = 8)
GMCa Range GMC Range t p
0 856.2 227.3–1935.0 843.5 321.3–1602.9 0.089 0.930
1 575.0 249.2–1241.3 454.7 112.2–1006.0 0.528 0.603
3.5 395.4 129.4–1162.3 75.8 7.0–507.9 2.641 0.016
8 984.5 299.6–1986.0 Negative – – –
24 637.3 240.7–1902.8 Negative – – –
aGMC is the abbreviation of geometric mean concentration.
Table 4 Age distribution of anti-CMV IgG seropositive
children
Age group (year) Total no. Positive no. (%)
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A total of 837 sera from 837 children (513 males) aged
0–8 years were tested for anti-CMV IgG. The IgG was
positive in 690 children and negative in 147 others. The
overall positive rate of anti-CMV IgG was 82.4% (83.2%
in boys and 81.2% in girls, χ2 = 0.584, p = 0.445). Gener-
ally, the positive rate slightly varied among the different
age groups. As shown in Table 4, anti-CMV IgG positive
rate was highest in infants <6-month old, decreased sig-
nificantly to 73.4% in the 6–12-month age, and increased
to 83.0% in the 1–2-year age (χ2 = 13.419, p = 0.001).
Then, the seroprevalence showed no significant fluctu-
ation until 8-year old (χ2 = 1.212, p = 0.796).
Since anti-CMV IgG may be negative but IgM is posi-
tive in the very early infection period, we tested anti-
CMV IgM in the 147 IgG negative children to clarify
whether some children were in this period; none of the
147 children was the IgM positive. To define whether
the anti-CMV IgG positive children were actively or la-
tently infected, we tested anti-CMV IgM in 280 samples
with the IgG concentration >500 IU/ml, and found that
23 (8.2%) were anti-CMV IgM positive; they were all bel-
low 6-year old and 12 (52.2%) were under 1-year old,
with the youngest only 1.5 months of age.
Primary CMV infection in childhood
Based on the profiles of anti-CMV IgG in the infants and
children, primary CMV infection appears to occur mainly
in the first year of life. Thus, we further tested CMV IgM
in all infants under 1-year old; the overall positive rate was
15.6% (29/186), higher than that in the other age groups.Table 3 Age distribution of anti-CMV IgM in 30 infected
children





Total 27 90Moreover, the CMV IgG avidity assay was performed in
the IgM positive individuals. On the whole, CMV IgG
avidity assay results indicated low AI (median 23.6%,
range 10.3–52.1%) in infants aged 3–12 months, whereas
intermediate or high AI (42.9%, 36.5–58.3%) in the 1–3-
month and 1–6-year age (62.8%, 14.8–87.6%).
In the retrospective study, as shown in Table 3, the
positive rate of anti-CMV IgM was highest (70%) during
1–3.5 months of age and the IgM was persistently nega-
tive in longitudinal sera of three individuals. In 2 of the
IgM negative infants, the concentration of anti-CMV
IgG decreased from 524.3 and 647.5 to 249.2 and
278.2 IU/ml at 1-month-old, respectively, and then
increased to 348.0 and 381.3 IU/ml at 3.5 months of age,
respectively. Therefore, the primary CMV infection oc-
curred before 3.5-month old in these two infants al-
though they were IgM negative, which may be related to
the fact that the IgM assay may lack sensitivity. In an-
other one, the IgG was negative at 8-month-old and
seroconversion was observed at 2-year old, suggesting a
primary CMV infection occurred during 8–24 months
old. Together with above two infants with increased
anti-CMV IgG at 3.5-month old, totally 76.7% (23/30)
underwent primary CMV infection during 1–3.5 months
of age. CMV IgG avidity assay also showed that all pri-
mary infected infants had CMV IgG AI <30%.<0.5 92 86 (93.5)
0.5–1 94 69 (73.4)
2 94 78 (83.0)
3 94 77 (81.9)
4 93 75 (80.6)
5 91 75 (82.4)
6 90 77 (85.6)
7 94 77 (81.9)
8 95 76 (80.0)
Total 837 690 (82.4)
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In the present study, we demonstrate that anti-CMV
IgG in pregnant women can efficiently transfer to their
fetuses and the maternal anti-CMV IgG in the majority
of newborns is higher than that in their mothers. More-
over, we validate that primary CMV infection in children
in China mainly occurred during 1–3.5 months of age.
Transplacental transfer of maternal IgG to the fetal
bloodstream is mediated by neonatal Fc receptor in syn-
cytiotrophoblasts of the placenta and contributes to the
passive immunity of newborns to pathogens. Maternal
IgG antibodies in full-term newborns are usually higher
than those in their mothers [9]. In agreement with previ-
ous studies [10,11], we found that anti-CMV IgG in
mothers transferred to the fetuses and anti-CMV IgG in
most cord sera exceeded the maternal levels. Further-
more, in the present study, we found that the seropreva-
lence of anti-CMV IgG was much higher in young
infants (<6 months old) as compared to older children
(Table 4), which is likely to be related to the persistence
of maternal antibodies in this group. Similarly, the inter-
mediate or high avidity antibodies detected in infants
<3 months of age may be explained by the transplacental
transfer of maternal antibodies.
Transplacentally acquired maternal antibodies may
protect infants against diseases in the early period of life.
In the present study, despite maternal anti-CMV IgG in
infants, primary CMV infection occurred early in child-
hood, indicating that maternal anti-CMV IgG can not
fully protect against CMV infection. On the other hand,
in spite of being infected, the children showed no symp-
toms related with CMV infection. Thus, maternal anti-
CMV IgG in infants may provide substantial protection
against symptomatic diseases or sequelae. This is similar
to the prophylactic purpose of hepatitis A vaccination
among children [12].
In developing countries, the incidence of primary
CMV infection has been reported to peak predominantly
in the first years of life [13,14]. However, in developed
countries, it occurs not only nearly at the end of child-
hood [15], but also in women of child-bearing age [16].
In our study, based on the kinetics of anti-CMV IgG
(Table 2), the seroconversion of anti-CMV IgM (Table 3)
and the results of CMV IgG avidity assay in children
with longitudinal sera, we concluded that primary CMV
infection in children mainly occurred before 3.5 months
of age, which is earlier than the infection age identified
before in developing countries [13,17]. For the children
in the second group, only cross-sectional serum samples
were available. It is possible that some CMV-infected
children did not develop detectable specific antibodies.
Therefore, some antibody negative infants may actually
have been infected. However, we consider that the pro-
portion of CMV IgG negative infected children shouldbe very small since the CMV IgG positive rates in chil-
dren at same age were similar in the retrospective and
cross-sectional groups (Table 4).
In the present study, the seroprevalence in the chil-
dren aged 0–8 years was around 80% and generally con-
stant from 2 to 8 years old (Table 4), which indicates
that there may be little CMV infection taking place be-
tween 2 and 8 years of age in this population. Also, we
found that 96.4% of the pregnant women were anti-
CMV IgG positive, which is in agreement with the rate
of anti-CMV IgG (93–98%) in child-bearing age women
in China [17,18]. The difference of the two rates may be
due to the variation in populations with different ages
since CMV infection through sexual contact is likely to
increase seroprevalence by the time of adulthood. Alter-
natively, the prevalence in the children may reflect the
positive rate in child-bearing age women in the future,
since social economic situation and hygienic status in
China have been greatly improved. However, with no
previously reported prevalence of anti-CMV IgG in
Chinese children, it is difficult to determine which is
more reasonable to explain the reduced prevalence in
the children. Therefore, further research is needed to
clarify this issue.
Our findings that most CMV infection in children oc-
curred before 3.5-month old also suggest that the CMV
infection source in children is mainly from mothers or
other family members since such young infants rarely
contact others in China. The results that one child of
the mother with negative anti-CMV IgG was persistently
negative for anti-CMV IgG also support the assumption.
Indeed, CMV in body fluids, such as breast milk may be
associated with the risk and severity of postnatal CMV
infection [19-21].
There are several limitations in the present study.
First, we defined the CMV infection in infants based on
the dynamic changes of anti-CMV IgG, which was quan-
titatively tested only using the Dia.Pro test system. Since
the dynamic ranges of different IgG ELISAs are highly
different, it would have been helpful to compare the
results of the Dia.Pro test system with other frequently
used ELISA system. However, in our study, the sera from
the mother-newborn pairs and longitudinal follow-up
were tested in parallel in each assay. Additionally, the
inter- and intra- assay variations were well within ac-
ceptable limits. Second, the gold standard for the diag-
nosis of CMV infection in early life is to detect the virus
in urine or saliva by viral culture and/or PCR. As our
study was retrospective, we did not have children’s urine
or saliva samples and only had children’s serum samples;
PCR has relatively lower sensitivity in detecting CMV
DNA in serum [22]. Thus, we did not perform viral cul-
ture and PCR to diagnose CMV infection. Third, 13.3%
of the infants at the age of 1 month (Table 3) were
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tain whether these infants were infected postnatally al-
though the anti-CMV IgG levels at 1-month old were
lower than in the cord blood. Nevertheless, according to
the seroconversion of CMV IgM and IgG, and the dy-
namic changes of IgG titers (decreasing, followed by in-
creasing) in infants [23], we can get the definitive
diagnosis of primary CMV infection at least in most of
the infants in the present study.
In view of the most CMV infection in children oc-
curred before 3.5-month old, Chinese children may ac-
quire CMV too early to be prevented by vaccination.
Therefore, we consider that children, at least in develop-
ing countries, should not be the target population for
the future licensed vaccine against CMV infection.
Methods
Subjects and serum specimens
The subjects recruited in this investigation included two
groups of children, and each child had a different family.
A retrospective group was composed of 112 singleton
full-term newborns and their 112 mothers. All mothers’
sera and cord blood samples, and longitudinal samples
from 41 infants at ages of 1, 3.5, 8, and 24 months re-
spectively were prospectively collected in a study on
hepatitis B vaccine conducted in Nanjing Drum Tower
Hospital from December 2006 to April 2009 [24]. The
mothers were 20–36 years of age (mean, 27.8 ± 2.6), 68
with vaginal delivery and 44 with caesarean section. The
male newborns were 59. All newborns were in good
health based on their birth records, with Apgar scores
>8 and body weights 2800–4600 g (3450.7 ± 369.6), and
had no symptoms related with CMV infection after birth
and during the follow-up. All the children did not attend
daycare since it is a widely accepted custom in China that
grandparents help to take care of their grandchildren.
The other group was composed of children who under-
went conventional physical examination in Nanjing
Children’s Hospital, June–September 2011. They were
recruited to investigate anti-CMV IgG seroprevalence
among children. We explained to the mothers/fathers
or guardians that their children’s remained sera after la-
boratory tests would be used for this study. After get-
ting the written informed consent from the mothers/
fathers or guardians and excluding those with abnormal
symptoms or laboratory tests, such as fever, congenital
malformations and liver function abnormalities, a total
of 837 sera from 837 children (aged 0–8 years, 513
boys), who were in good health and had no symptoms
related with CMV infection, were collected.
This study was approved by the institutional review boards
of Nanjing Drum Tower Hospital (2011OG02NDTH) and
Nanjing Children’s Hospital (NCH2011518). For the
retrospective cohort, since the mothers consented inthe other study [24], mothers’ and children’s serum
samples were used in the present study via an exemp-
tion approved by the institutional review board of Nan-
jing Drum Tower Hospital. For the cross-sectional
group, mothers/fathers or guardians gave the written
informed consent for the use of their children’s sera.
Quantification of anti-CMV IgG
Sera were quantitatively tested for anti-CMV IgG using
a commercial enzyme-linked immunosorbent assay
(ELISA) kit (Dia.Pro Diagnostic Bioprobes, Milano, Italy)
[25-27]. The kit contains the microplate coated with na-
tive CMV antigens, which were inactivated and highly
purified by sucrose gradient centrifugation. Additionally,
the kit contains human plasma derived calibrators with
anti-CMV IgG at concentrations of 0, 0.5, 1, 2, 4, and
8 IU/ml, which were titrated on WHO standard (pro-
posed international standard). In the measurement,
paired maternal and cord sera, firstly diluted 1:101 with
diluent (2% casein, 10 mM Tris-citrate buffer and 0.1%
Tween 20), were tested in parallel, and positive and
negative controls provided in the kit were also included.
Calibration curves were established for each test. Based
on the manufacturer’s instruction, the diluted sample
with a concentration >0.5 IU/ml was considered positive
for anti-CMV IgG, while the sample with a concentra-
tion ≤0.5 IU/ml was considered negative. When the IgG
concentration was beyond the upper detection limit
(8 IU/ml), the sera were retested by further dilution.
Each test showed good linearity.
Detection of anti-CMV IgM
Anti-CMV IgM was measured by the CMV IgM capture
immunoassay (Dia.Pro Diagnostic Bioprobes). The kit
contains the microplate coated with anti-human IgM,
which was derived from mouse monoclonal antibody
and purified by affinity chromatography. Anti-CMV IgM
positive and negative human plasma controls were pro-
vided in the kit. In each measurement, serum samples
were diluted same as in detection of anti-CMV IgG, and
positive and negative controls were included. As recom-
mended by the manufacturer, the cut-off value was cal-
culated as follows: cut-off = OD450 for negative control
+ 0.250. The test result was interpreted as a ratio of the
sample OD450 and the cut-off value (S/Co). The sample
was considered positive if S/Co value was >1.2, indeter-
minate if it was 1.0–1.2, and negative if it was <1.0. The
indeterminate sample was retested; the sample was con-
sidered positive if S/Co value was 1.0–1.2 or >1.2, and
negative if it was <1.0.
CMV IgG avidity assay
CMV IgG avidity index (AI) was measured by 8 M urea
denaturation procedures using CMV IgG ELISA kit
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[28,29]. Briefly, for each sample, a 50 μl aliquot of appro-
priately diluted serum was added to CMV antigen-
coated wells in duplicate [30]. Then 50 μl 8 M urea and
50 μl specimen diluent (2% casein, 10 mM Tris-citrate
buffer pH 6.0, 0.1% Tween 20) were applied to the de-
naturation and reference wells respectively. The assay
was then continued according to the manufacture’s
recommendations. For a given serum, the AI was calcu-
lated as follows: (net OD in the presence of urea/net OD
in the absence of urea) × 100%. An AI lower than 30%
was considered as low, between 30% and 50% as inter-
mediate, and greater than 50% as high-avidity antibodies.Statistical analysis
Data were analyzed with SPSS version 17.0. Statistical
comparisons of the IgG levels between different groups
were analyzed by t-test. Chi-squared test or Fisher’s
exact test was used for categorical data. Linear regres-
sion analysis was performed in correlating maternal and
cord blood titers. A p value less than 0.05 was consid-
ered statistically significant.
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